The MedicX Fund Limited
27 December 2006
For immediate release 27 December 2006
MedicX Fund Limited
('MedicX Fund', 'the Fund' or 'the Company')
Acquisition of Twelve New Properties
MedicX Fund, the specialist investor in modern purpose built primary healthcare
properties which listed on the Official List of the London Stock Exchange on 2
November 2006, today announces that it has completed the acquisition of a
further 11 new properties, nine of which have already been built with two under
construction and due to complete in May and October 2007. The properties are
currently owned by Medcentres 2006 Limited ('Medcentres 2006') which will be
acquired by MedicX Fund for £10.3 million from NJ Arnold. Medcentres 2006 has
debt net of cash of £26.3 million and a working capital balance of £0.6 million.
In addition, MedicX Properties I Ltd (a subsidiary of the Fund) has contracted
to acquire a property in Wisbech for £6 million directly from NJ Arnold. The
aggregate purchase price is £16.3 million with £15.8 million in cash and
£510,000 in MedicX Fund shares issued at a price of £1.02 per share paid to NJ
Arnold. The two projects under construction require a further £4.2m to
complete; the total cost of the 12 acquired properties when all are complete is
therefore £46.2m before purchaser costs. Medcentres 2006 Limited will be
renamed MedicX Properties IV Ltd. The Fund will refinance the existing debt
using its £100 million loan from Norwich Union at its 5% fixed total borrowing
cost.
The 12 properties are located in Rugby, Norwich, Braintree, Gravesend,
Lymington, Ringwood, Wareham, March, Bridport, Evesham, Verwood and Wisbech.
The current rent of the 12 properties is £2,789,783 per annum in aggregate and
the properties have been valued by DTZ Debenham Tie Leung, valuers to the MedicX
Fund, at £49.6 million net of 5.75% purchaser costs. The current rent and
valuation assumed the two under construction are completed. The 12 new sites
bring the total number of primary healthcare properties owned by the MedicX Fund
to 34.
In addition, the MedicX Group has secured an exclusive option to forward fund
new properties developed by NJ Arnold and Medcentres until 1 January 2009 which
can be extended with the agreement of both parties.
This acquisition was not included in the pipeline reported in the Medicx Fund
IPO prospectus but is in line with the strategy of the business.
Keith Maddin, Chairman of MedicX Group, said: 'We are delighted to have finished
the year on such a positive note. In our first two months the MedicX Fund has
assembled a portfolio of 34 modern primary healthcare properties spread across
England and Wales. The £67.8 million invested (before purchaser costs and on
top of the £46 million initial portfolio) in new properties exceeds the target
assumed for the first twelve months presented in the prospectus and has been
valued by DTZ at £74.3 million. The Fund's pipeline has been enhanced following
the recent transactions with Oakapple and Medcentres. We look forward to 2007
and the further opportunities that may arise.'
End
For further information please contact:
MedicX Group +44(0) 1252 704 272
Keith Maddin, Chairman
Mike Adams, Managing Director
Buchanan Communications +44 (0) 20 7466 5000
Charles Ryland / Lisa Baderoon / Mary-Jane Johnson
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.